Does a Pfizer-Allergan Deal Make Sense?
Umer Raffat, Evercore ISI research analyst, comments on Pfizer possibly being in advanced talks to buy Allergan for as much as $380 per share. He speaks with Bloomberg's Betty Liu on "Bloomberg Markets." (Source: Bloomberg)
Most Recent Videos
Stockton, Wilson on Fundamentals Versus Technicals
55:43 - Katie Stockton, chief technical strategist at BTIG, and Mike Wilson, chief U.S. equity strategist at Morgan Stanley, discuss the outlook for markets and impact from President Trump. They speak with Bloomberg's Alix Steel and Jonathan Ferro on "Bloomberg Daybreak: Americas." (Source: Bloomberg)